Experimental cell therapy targets autoimmune diseases that Won't quit

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and check if the therapy helps control the disease. The goal is to see if this approach is safe enough to study further.